Let’s take a closer look at the June 2016 earnings estimates, particularly the things investors should pay close attention to.
Advertisement
The company’s revenue rose 1 percent to $9.84 billion, above analysts’ average estimate of $9.78 billion.
After upcoming financial results, all eyes will be on the outlook or guidance for the next reporting quarter (September 2016).
Revenues checked in at $9.84 billion, ever-so-slightly topping the $9.78 billion analysts predicted. It now expects full-year revenue to come in between $39.1 billion to $40.1 billion, up from a prior $39.0 billion to $40.2 billion range.
Merck said it now expects full-year earnings in the range of $1.98 to $2.08 per share, excluding one-time items.
According to consensus agreement of 19 analysts Merck & Co., Inc.
Societe Generale has been a brokerage house following shares of Merck & Co. Inc.
If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $0.85 while the company reported $0.89 EPS on 5/5/2016 BMO with a difference of 0.04 marking a surprise factor of 4.71%. News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Company, Inc. with MarketBeat.com’s FREE daily email newsletter. Current revenue movements show that, the company has set average revenue estimates of 9.78B covering forecast of 16 analysts. (NYSE:MRK) plunged -0.29% or -0.17 points during previous trade after opening at the price of $58.52, a total of 7.29M shares exchanged hands compared with its average trading volume of 9.67M shares. Wall Street had projected $10.35B and $0.91, respectively. Past 5 years growth of Merck & Co., Inc.
02/03/2016 – Merck & Company, Inc. had its “hold” rating reiterated by analysts at S&P Capital IQ. Another noteworthy analyst activity was recorded on January 27, 2016.
01/27/2016 – Merck & Company, Inc. was downgraded to “neutral” by analysts at Bank of America Merrill Lynch.
Advertisement
Merck & Co. Inc.is trading up 32.15 percent versus 1-year low of $45.69 and stands -2.65 lower from its peak of $60.07. Adjusted earnings should be $3.67 to $3.77 a share, compared with a past projection of $3.65 to $3.77. MRK EVP & Pres-Global Human Health Schechter Adam H also sold 50,000 shares, at a stock price of $57.69. The stock has risen almost 2 percent in the last 12 months.
